TY - JOUR T1 - Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2973 LP - 2977 VL - 25 IS - 4 AU - CHIKARA KUNISAKI AU - TOSHIO IMADA AU - ROPPEI YAMADA AU - SHINSUKE HATORI AU - HIDETAKA ONO AU - YUICHI OTSUKA AU - GORO MATSUDA AU - MASATO NOMURA AU - HIROTOSHI AKIYAMA AU - AKIRA KUBO AU - HIROSHI SHIMADA Y1 - 2005/07/01 UR - http://ar.iiarjournals.org/content/25/4/2973.abstract N2 - Background: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. Patients and Methods: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. Results: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. Conclusion: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -